Table 3.

Treatment and complications in 33 patients diagnosed with butterfly glioblastoma between 01/01/2007 and 31/12/2014

Primary treatment
Surgery
Resection	4 (12.1%)
Biopsy	11 (33.3%)
None	18 (54.5%)
Chemoradiotherapy
Stupp protocola	8 (24.2%)
Less-intensiveb	19 (57.6%)
None	6 (18.2%)
Number of adjuvant TMZ courses	3 (1–9)
Anti-tumor treatment last 30 days of life	6 (18.2%)
Complications during follow-up
Surgical complicationsc	2 (13.3%)
Epileptic seizure	13 (39.4%)
Venous thromboembolism	10 (30.3%)
Hematotoxicityd	3 (15.8%)
Osteoporosis	4 (12.1%)
Treatment at recurrence (n = 18)e
Best supportive care	11 (61.1%)
Surgical resection	2 (11.1%)
Stereotactic radiosurgery	1 (5.6%)
Re-irradiation	0 (0.0%)
TMZ monotherapy	5 (27.8%)
CCNU-based chemotherapy (PCVf)	1 (5.6%)
Bevacizumab and nitrosoureas (CCNU or BCNU)	2 (11.1%)

Number of TMZ courses presented as median (range), all others as absolute numbers (%).

CTCAE, common terminology criteria for adverse events; TMZ, temozolomide; CCNU, cyclonexyl-chloroethyl-nitrosourea (lomustine); BCNU, bis (chloroethyl) nitrosourea (carmustine).

^aDefined as the completion of radiation therapy (60 Gy in 2 Gy fractions) with concurrent TMZ and at least one of six planned TMZ monotherapy courses).

^bIncluded 16 patients with hypofractionated radiation therapy with or without TMZ and three patients with standard fractionated radiation therapy with TMZ to a less extent.

^cComplications among 15 patients who had undergone biopsy or resection included cerebral infarction and paresis (n=1) and increasing dysphasia (n=1).

^dCTCAE ≥ grade 3 among 19 patients receiving TMZ.

^eNumbers include 18 patients where relapse was detected, while two patients with no sign of recurrence during follow-up and 13 patients who had a continuous deterioration and died without being diagnosed with recurrence were not included.

^fProcarbazine, Lomustine (CCNU), and Vincristine.